Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2012-04-20 | Walter C. Herlihy joined Repligen in March 1996 as President, Chief Executive Officer and Director in connection with Repligen’s merger with Glycan Pharmaceuticals, Inc. From July 1993 to March 1996, Mr. Herlihy was the President and CEO of Glycan Pharmaceuticals, Inc. From October 1981 to June 1993, he held numerous research positions at Repligen, most recently as Senior Vice President, Research and Development. Mr. Herlihy holds an A.B. in chemistry from Cornell University and a Ph.D. in chemistry from MIT. The Board of Directors believes Mr. Herlihy’s qualifications to sit on the Board of Directors include his decades of experience in the pharmaceutical field, including over 15 years as President and Chief Executive Officer of the Company, and his deep understanding of the Company’s historical and current business strategies, objectives and products. |
| 2013-04-09 | Walter C. Herlihy, Ph.D. joined Repligen in March 1996 as President, Chief Executive Officer and Director. ... Mr. Herlihy serves as the Chairperson of the Science and Technology Committee. ... The Board has determined that each of the directors who has served during the fiscal year ended December 31, 2012, with the exception of Mr. Herlihy, has no material relationship with the Company and is independent. ... Director Compensation Table for the Fiscal Year Ended December 31, 2012 does not list compensation for Mr. Herlihy as a director. |
| 2014-04-08 | Walter C. Herlihy 62 President, Chief Executive Officer and Director; Summary Compensation Table for the Fiscal Years ended December 31, 2013: Total $1,039,474. |
Data sourced from SEC filings. Last updated: 2025-10-11